Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Completed · Phase 2

Conditions studied: Neuroendocrine Tumors

In brief

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

Key facts

Study ID

NCT02279602

Run by

Mateon Therapeutics

People needed

7

Starts

2014-12-01

Expected to finish

2016-08-01

Last updated by the study team

2018-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has been treated in the OXiGENE-sponsored Phase 2 study OX4218s

You may not qualify if…

• Subject has not received fosbretabulin treatment in the study OX4218s

Where it is running

• Stanford University School of Medicine — Stanford, California, United States
• Markey Cancer Center, Clinical Research Office — Lexington, Kentucky, United States
• Montefiore — The Bronx, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Froedtert Hospital, Medicial College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.